These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 26983667)

  • 1. Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology.
    Helkin A; Stein JJ; Lin S; Siddiqui S; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):107-18. PubMed ID: 26983667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial lipoproteins and the molecular regulation of vascular homeostasis.
    Botham KM; Wheeler-Jones CP
    Prog Lipid Res; 2013 Oct; 52(4):446-64. PubMed ID: 23774609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [LDL: from metabolic syndrome to instability of the atherosclerotic plaque].
    Siqueira AF; Abdalla DS; Ferreira SR
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):334-43. PubMed ID: 16767300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.
    Hurtubise J; McLellan K; Durr K; Onasanya O; Nwabuko D; Ndisang JF
    Curr Atheroscler Rep; 2016 Dec; 18(12):82. PubMed ID: 27822682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
    Gonzalez L; Helkin A; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL and atherothrombotic vascular disease.
    Annema W; von Eckardstein A; Kovanen PT
    Handb Exp Pharmacol; 2015; 224():369-403. PubMed ID: 25522995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS project.
    Genoud M; Wietlisbach V; Feihl F; Mermod A; Morin D; Darioli R; Nicod P; Mooser V; Waeber B; Hayoz D; Waeber G
    Angiology; 2008; 59(4):484-92. PubMed ID: 18388087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques.
    Rai V; Agrawal DK
    Can J Physiol Pharmacol; 2017 Oct; 95(10):1245-1253. PubMed ID: 28746820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern methods of diagnosis dyslipidemia ].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Patol Fiziol Eksp Ter; 2016; 60(1):65-72. PubMed ID: 29215251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonlinear dynamics of early atherosclerotic plaque formation may determine the efficacy of high density lipoproteins (HDL) in plaque regression.
    Chalmers AD; Bursill CA; Myerscough MR
    PLoS One; 2017; 12(11):e0187674. PubMed ID: 29161303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage Phenotype and Function in Different Stages of Atherosclerosis.
    Tabas I; Bornfeldt KE
    Circ Res; 2016 Feb; 118(4):653-67. PubMed ID: 26892964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice.
    Arnaud C; Poulain L; Lévy P; Dematteis M
    Atherosclerosis; 2011 Dec; 219(2):425-31. PubMed ID: 21917260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia.
    Llurba E; Casals E; Domínguez C; Delgado J; Mercadé I; Crispi F; Martín-Gallán P; Cabero L; Gratacós E
    Metabolism; 2005 Nov; 54(11):1504-9. PubMed ID: 16253640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses.
    Navratil AR; Vozenilek AE; Cardelli JA; Green JM; Thomas MJ; Sorci-Thomas MG; Orr AW; Woolard MD
    Atherosclerosis; 2015 Oct; 242(2):424-32. PubMed ID: 26288136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis.
    Yu XH; Zheng XL; Tang CK
    Adv Clin Chem; 2015; 71():171-203. PubMed ID: 26411415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression.
    Horio E; Kadomatsu T; Miyata K; Arai Y; Hosokawa K; Doi Y; Ninomiya T; Horiguchi H; Endo M; Tabata M; Tazume H; Tian Z; Takahashi O; Terada K; Takeya M; Hao H; Hirose N; Minami T; Suda T; Kiyohara Y; Ogawa H; Kaikita K; Oike Y
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):790-800. PubMed ID: 24526691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between insulin resistance and the development of cardiovascular disease.
    Ormazabal V; Nair S; Elfeky O; Aguayo C; Salomon C; Zuñiga FA
    Cardiovasc Diabetol; 2018 Aug; 17(1):122. PubMed ID: 30170598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.